FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Thorp Clay				2. Issuer Name and Ticker or Trading Symbol PhaseBio Pharmaceuticals Inc [PHAS]								Relationship neck all appli X Directo	cable)	ig Pers	son(s) to Iss 10% Ov			
	ASEBIO PH	IARMACEUTIC		2.		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2021							Officer below)	(give title		Other (s below)	specify	
1 GREAT VALLEY PARKWAY, SUITE 30				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)						
(Street) MALVE	RN PA	A	19355										X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transar Date (Month/D.				Execution Date,		Transaction Disposed Of Code (Instr. 5)		ties Acquired (A) or I Of (D) (Instr. 3, 4 and		Benefici	s Illy ollowing	Form (D) o	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount	(A) o (D)	Price	Transact	saction(s) c. 3 and 4)			(IIISU. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Treecurity or Exercise (Month/Day/Year) if any Co		ansaction of E ode (Instr. Derivative (6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title an of Securit Underlyin Derivative (Instr. 3 au			ies g Security	8. Price of Derivative Security (Instr. 5)		re Coss Fally Coss g (f	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				c	ode \	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Non- employee Director Stock Option (right to buy)	\$3.53	06/03/2021			A		14,000		(1)	0	6/03/2031	Common Stock	14,000	\$0	14,00	0	D	

Explanation of Responses:

1. The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2022 annual meeting, subject to the reporting person's continuous service through each such date

Remarks:

/s/ John P. Sharp, Attorney-in-06/04/2021 fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.